Diaxonhit Stock Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 227M 263M 209M 196M 368M 24.89B 372M 2.46B 960M 12.21B 987M 966M 42.19B | P/E Ratio 2026 * |
19.9x | P/E Ratio 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 195M 226M 179M 168M 316M 21.37B 320M 2.11B 824M 10.49B 847M 829M 36.23B | EV / Sales 2026 * |
1.11x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 13/06/2023 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 10/10/2023 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 01/01/2019 | |
Michel Picot
BRD | Director/Board Member | 73 | 27/06/2019 |
| Director/Board Member | 69 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 265M | |
| -0.12% | +1.04% | -13.08% | -12.43% | 43.58B | |
| -2.17% | +5.45% | +285.76% | +522.83% | 34.03B | |
| +0.44% | -2.46% | +14.20% | -17.35% | 29.77B | |
| -1.60% | -2.54% | -2.12% | +31.28% | 29.82B | |
| -0.29% | +9.47% | +13.95% | +21.93% | 25.42B | |
| +3.54% | +12.34% | - | - | 13.87B | |
| -1.26% | +0.81% | +54.77% | +109.24% | 13.35B | |
| -1.04% | -3.33% | +3.98% | +3.91% | 12.85B | |
| -1.18% | -0.61% | +105.37% | +75.32% | 12.22B | |
| Average | -0.55% | +2.03% | +57.85% | +91.84% | 23.88B | |
| Weighted average by Cap. | -0.54% | +2.02% | +59.38% | +102.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 204M 162M 152M 286M 19.32B 289M 1.91B 745M 9.48B 766M 750M 32.76B | - |
| Net income | 11.6M 13.47M 10.68M 10.03M 18.84M 1.27B 19.05M 126M 49.14M 625M 50.52M 49.45M 2.16B | - |
| Net Debt | -32M -37.15M -29.45M -27.67M -51.97M -3.52B -52.56M -348M -136M -1.73B -139M -136M -5.96B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
